Monoclonal gammopathy of undetermined significance (MGUS)—not so asymptomatic after all

Oliver C. Lomas, Tarek H. Mouhieddine, Sabrin Tahri, Irene M. Ghobrial

Research output: Contribution to journalReview articlepeer-review

21 Scopus citations

Abstract

Monoclonal Gammopathy of Undetermined Significance (MGUS) is considered to be a benign precursor condition that may progress to a lymphoproliferative disease or multiple myeloma. Most patients do not progress to an overt condition, but nevertheless, MGUS is associated with a shortened life expectancy and, in a minority of cases, a number of co-morbid conditions that include an increased fracture risk, renal impairment, peripheral neuropathy, secondary immunodeficiency, and cardiovascular disease. This review aims to consolidate current evidence for the significance of these co-morbidities before considering how best to approach these symptoms and signs, which are often encountered in primary care or within a number of specialties in secondary care.

Original languageEnglish
Article number1554
Pages (from-to)1-16
Number of pages16
JournalCancers
Volume12
Issue number6
DOIs
StatePublished - Jun 2020

Keywords

  • Fracture
  • MGRS
  • MGUS
  • Multiple myeloma
  • Neuropathy
  • Osteoporosis
  • Paraprotein

Fingerprint

Dive into the research topics of 'Monoclonal gammopathy of undetermined significance (MGUS)—not so asymptomatic after all'. Together they form a unique fingerprint.

Cite this